UNSPSC 51343805: Interferon alfa-2b/ribavirin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343805 Interferon alfa-2b/ribavirin is a Commodity code that in practice captures state and local procurement of pharmaceutical products and medical supplies far broader than the code's nominal name suggests. Recent solicitations under this code include emergency medical consumables (respiratory equipment, cardiac monitoring devices, endotracheal tubes, bandaging materials), naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers, and direct-to-manufacturer prescription programs. The issuing bodies span county health departments, city fire and rescue divisions, state health and human services agencies, and multi-state cooperative purchasing alliances. Procurement mechanisms include formal IFBs with sealed bidding, RFPs for manufacturer contracts and program design, and RFIs for market intelligence and vendor capability assessment. Most solicitations require vendors to demonstrate compliance with FDA regulations, cGMP standards, and the Drug Supply Chain Security Act, maintain substantial insurance coverage, and often use authorized distribution channels or wholesaler networks rather than direct supply relationships.

Recent activity appears concentrated in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The City of Tampa's Purchasing Department solicited IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5 percent bid discount reserved for certified Small Local Business Enterprises. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, covering participating state and local government facilities across multiple states including Oregon.